What is the price of Entropy Neurodynamics Limited (ENP)

The price of Entropy Neurodynamics Limited (ENP) is $0.02468497

What is the market cap of Entropy Neurodynamics Limited (ENP)

The market cap of Entropy Neurodynamics Limited (ENP) is $40.28M

Entropy Neurodynamics Limited (ENP) Price History

Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.

Year	Performance
2026 (TTM)	14.81%
2025	0.00%

Year

Performance

2026 (TTM)

14.81%

2025

0.00%

Company	Stock price	Change 1y%	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$546.54	38.59%	US
Argenx SE ARGX.US	$1.04K	56.71%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Moderna, Inc. MRNA.US	$138.98	416.85%	US
Lonza Group AG LONN.SW	$761.87	7.04%	CH

Company

Stock price

Change 1y%

Country